These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 12698179)
1. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Kosmas C; Tsavaris N; Malamos N; Stavroyianni N; Gregoriou A; Rokana S; Polyzos A Br J Cancer; 2003 Apr; 88(8):1168-74. PubMed ID: 12698179 [TBL] [Abstract][Full Text] [Related]
2. Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study. Kosmas C; Tsavaris N; Mylonakis N; Tsakonas G; Gassiamis A; Skopelitis H; Polyzos A; Malamos N; Karabelis A J Chemother; 2007 Jun; 19(3):322-31. PubMed ID: 17594929 [TBL] [Abstract][Full Text] [Related]
3. Dose escalation of docetaxel and ifosfamide in patients with advanced breast cancer failing prior anthracyclines: mature results of a phase I-II study. Cosmas C; Tsavaris N; Malamos N; Tsakonas G; Gassiamis A; Skopelitis H; Soukouli G; Polyzos A; Mylonakis N; Karabelis A J BUON; 2005; 10(3):337-46. PubMed ID: 17357187 [TBL] [Abstract][Full Text] [Related]
4. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines. Kosmas C; Tsavaris N; Malamos N; Tsakonas G; Gassiamis A; Polyzos A; Mylonakis N; Karabelis A Invest New Drugs; 2007 Oct; 25(5):463-70. PubMed ID: 17370037 [TBL] [Abstract][Full Text] [Related]
5. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer. Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398 [TBL] [Abstract][Full Text] [Related]
6. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956 [TBL] [Abstract][Full Text] [Related]
7. Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study. Specenier P; Rasschaert M; Van den Brande J; Dyck J; Schrijvers D; Huizing MT; Vermorken JB Anticancer Drugs; 2010 Mar; 21(3):306-12. PubMed ID: 20087171 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Awada A; Albanell J; Canney PA; Dirix LY; Gil T; Cardoso F; Gascon P; Piccart MJ; Baselga J Br J Cancer; 2008 May; 98(9):1500-7. PubMed ID: 18454159 [TBL] [Abstract][Full Text] [Related]
9. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Mackey JR; Tonkin KS; Koski SL; Scarfe AG; Smylie MG; Joy AA; Au HJ; Bodnar DM; Soulieres D; Smith SW Clin Breast Cancer; 2004 Oct; 5(4):287-92. PubMed ID: 15507175 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Delozier T; Guastalla JP; Yovine A; Levy C; Chollet P; Mousseau M; Delva R; Coeffic D; Vannetzel JM; Zazzi ES; Brienza S; Cvitkovic E Anticancer Drugs; 2006 Oct; 17(9):1067-73. PubMed ID: 17001180 [TBL] [Abstract][Full Text] [Related]
11. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment. Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Mitchell PL; Basser R; Chipman M; Grigg A; Mansfield R; Cebon J; Davis ID; Appia F; Green M Ann Oncol; 2004 Apr; 15(4):585-9. PubMed ID: 15033663 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. Kosmas C; Agelaki S; Giannakakis T; Mavroudis D; Kouroussis Ch; Kalbakis K; Papadouris S; Souglakos J; Malamos N; Georgoulias V Oncology; 2002; 62(2):103-9. PubMed ID: 11914594 [TBL] [Abstract][Full Text] [Related]
14. A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer. Bayo J; Lomas M; Salvador J; Moreno A; Ruiz M; Rodríguez A; Fuentes J; Fernández-Freire A; Bernabé R; Fernández A Clin Transl Oncol; 2008 Dec; 10(12):817-25. PubMed ID: 19068453 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours. Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer. Kosmas C; Tsavaris N; Koutras A; Makatsoris T; Mylonakis N; Tzelepis G; Dimitrakopoulos A; Spyropoulos K; Polyzos A; Karabelis A; Kalofonos HP Oncology; 2005; 69(4):333-41. PubMed ID: 16282711 [TBL] [Abstract][Full Text] [Related]
18. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527 [TBL] [Abstract][Full Text] [Related]
19. Biweekly docetaxel and vinorelbine with granulocyte colony-stimulating factor support for patients with anthracycline-resistant metastatic breast cancer. Gómez-Bernal A; Cruz JJ; Olaverri A; Arizcun A; Martín T; Rodríguez CA; Martín G; Fonseca E; Sánchez P Anticancer Drugs; 2005 Jan; 16(1):77-82. PubMed ID: 15613908 [TBL] [Abstract][Full Text] [Related]
20. Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer. Lortholary A; Delozier T; Monnier A; Bourgeois H; Bougnoux P; Tubiana-Mathieu N; Riffaud JCh; Besson D; Lotz V; Gamelin E Br J Cancer; 2003 Jun; 88(11):1669-74. PubMed ID: 12771978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]